Extracellular vesicles: setting-up the path to IND with advanced characterization packages

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Extracellular vesicles: setting-up the path to IND with advanced characterization packages

Extracellular vesicles (EVs) are a promising delivery vehicle for various genetic therapeutics. Advanced characterization plays a foundational role in the development of successful EV-based therapeutics, and remains a bottleneck due to the extensive cargo and size variations of EVs. Leveraging established analytical methods early can be key to steering your product development successfully.

In this webinar, our experts will discuss the intricacies of producing EV-based therapies, emphasizing the importance of precise analytics and process design to maintain control over product quality throughout clinical development, measuring critical quality attributes (CQAs) accurately without over-complicating the validation process. This session will offer a strategic roadmap for EV analytics and process design to ensure the success of your EV therapeutics.

Why characterization is the cornerstone to advancing EV therapeutics
Leveraging established methods in the clinic to achieve in-depth characterization of CQAs
The path to IND and beyond

Davide Zocco

Director, Site Management at Lonza

Davide Zocco, Head of Exosomes Development and Site Head of the Lonza site in Siena, Italy, leads R&D programs and process development services to support companies developing exosome-based therapeutics. He was a board member at his former company, Exosomics, Lonza’s strategic R&D partner. He is an author of peer-reviewed publications in high-profile journals which include Nature Chemical Biology, PNAS, and American Journal of Pathology (>5000 citations), and of four patents in the extracellular vesicle field. He achieved a PhD from University College Dublin, Ireland, and previously a post-doctoral research fellow at Harvard Medical School, USA.